AstraZeneca revises Covid vaccine data with lower efficacy rate after accuracy questions

AstraZeneca issued updated phase three trial data for its Covid-19 vaccine on Wednesday after facing criticism earlier this week over a preliminary report from its U.S. study. The company now says its vaccine is 76% effective in protecting against symptomatic ...

from Google Alert - Business https://ift.tt/39dnRXD
AstraZeneca issued updated phase three trial data for its Covid-19 vaccine on Wednesday after facing criticism earlier this week over a preliminary report from its U.S. study. The company now says its vaccine is 76% effective in protecting against symptomatic ... https://ift.tt/eA8V8J

Comments

Popular posts from this blog

Jobless Rate Drops

Electrolytic Fixed Power Capacitors Market Competitive intelligence & regional outlook 2020

USU project among finalists for $3 million solar energy tech prize